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Abstract 
Described here is a method for the measurement of the radio-metabolites of the 
positron emission tomography (PET) radiotracer [6-O-methyl-11C]diprenorphine 
([11C]diprenorphine) using in-line solid phase extraction (SPE) combined with radio-HPLC 
analysis. We believe that this method offers a reliable and reproducible approach to 
[11C]diprenorphine metabolite analysis. In addition, different SPE stationary phases are 
assessed for their efficiency for loading, retention and elution of the parent molecule and its 
metabolites. Having assessed C4, phenyl and C18 stationary phase we concluded that a C18 
SPE was optimal for our method. Finally, in silico predictions of diprenorphine metabolism 
were compared with in vivo metabolism of [11C]diprenorphine induced by hepatic 
microsomal digestion and analysed by MALDI mass spectrometry. It was found that there 
was a high degree of agreement between the two methods and in particular the formation of 
the diprenorphine-3-glucuronide metabolite.        
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Introduction 
[6-O-methyl-11C]diprenorphine ([11C]diprenorphine) is an important positron 
emission tomography (PET) radioligand which binds to multiple subtypes of opioid receptor 
(µ, δ and κ sites) with high affinities (Ki values of approximately 0.2 nM)[1]. Diprenorphine 
acts as an antagonist at µ and δ opioid receptors and as a weak agonist at the κ receptors[2]. 
Opioid receptors are associated with a wide variety of physiological processes including 
analgesia, epilepsy[3], central post stroke pain[4], dysphoria and euphoria[5]. 
[11C]Diprenorphine PET is a powerful tool to study the role of the endogenous opioid system 
in these biological processes, allowing quantitative imaging of opioid receptor density and 
displacement by endogenous opioids[2, 5-13]. However, [11C]diprenorphine will undergo 
metabolism in vivo and this is significant for PET imaging[6, 9, 14]. If radiolabelled 
metabolites are produced on the timescale of a clinical PET scan then a method is required to 
determine the radiometabolite concentrations as a function of time. 
Having the ability to identity 11C labelled metabolites is also important in order to 
estimate their influence on the scan data. For example, knowing whether radiometabolites 
cross the blood-brain barrier and their affinity for opioid receptors is of high importance to 
accurately model [11C]diprenorphine binding in the brain. At various time points during the 
PET scanning session the ratio of parent [11C]diprenorphine to each radio-metabolite needs to 
be established. An accurate correction for arterial plasma radiometabolite concentrations is 
necessary to derive a correct plasma input function. This in turn is needed to accurately 
model quantitative binding of [11C]diprenorphine to available opioid receptors in the brain[6]. 
A variety of methods are available for the extraction and measurement of radiotracer 
metabolites. The measurement of radio-metabolites in human plasma is very challenging. The 
radio-metabolite concentrations are low and diminish with time, requiring that relatively large 
volumes of plasma (5 mL) be analysed. Such volumes of plasma cannot be analysed directly 
using analytical HPLC (< 4.6 mm i.d. columns) without overloading the column, yielding 
very poor chromatographic resolution and dramatically shortening HPLC column life. 
Chromatographic detection normally employs flow-through detectors, giving an immediate, 
real time measurement of chromatographic peak height and area, however the short sample 
residence time in the detector leads to poor detection limits. This can be improved by 
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collecting fractions of eluent and measuring each fraction off-line in a radio-detector, thus 
extending measurement time significantly, limited only by the availability of radio-detectors 
for the number of samples generated. Large plasma samples can be injected onto preparative 
scale HPLC columns; however these have correspondingly higher mobile phase flow rates 
and generate larger volume fractions for off-line detection[15]. Widely available multi-well 
detectors such as the Perkin Elmer 10-well automatic gamma counter are limited in sample 
capacity and the chromatography is best performed using an analytical scale column to allow 
eluted fractions to be collected in the 1 – 3 mL volume range.  
The alternative to direct analysis (HPLC column injections) is to remove the protein 
fraction from the sample and pre-concentrate the metabolites into smaller volume samples. 
This has been achieved in a number of ways 1) protein precipitation 2) liquid-liquid 
extraction 3) metabolite trapping by SPE. The efficacy of these methods will depend on the 
lipophilicity of the parent tracer and metabolites and the extent to which these species are co-
precipitated with plasma proteins. However these methods have inherent problems associated 
with them. Performing protein precipitation/extraction can lead to the loss of metabolites 
which may be bound to the plasma proteins. Furthermore using a vacuum manifold with SPE 
cartridge extraction may lead to the loss of volatile metabolites present in the sample. We 
believe that the use of in-line SPE to clean-up and concentrate the sample followed by HPLC 
analysis is the optimum method of metabolite analysis. With this method it is possible to start 
with a 5 mL blood sample which can be processed and worked up so that metabolite 
measurements can be performed on an analytical HPLC column. Figures 1 – 3 depict the 
configuration of in-line SPE followed by HPLC for [11C]diprenorphine metabolite analysis. 
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Figure 1: Schematic of in-line SPE and HPLC system. Valves are shown in sample inject position.  
 
Figure 2: Schematic of in-line SPE and HPLC system. Valves are shown in SPE load position.  
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Figure 3: Schematic of in-line SPE and HPLC system. Valves are shown in SPE elution position. 
Diprenorphine has a cLogP value calculated as 2.57, so it is important to select the 
appropriate SPE and HPLC stationary phases which will retain [11C]diprenorphine as well as 
the less lipophilic radio-metabolites such as [11C]diprenorphine-3-glucuronide (calculated 
cLogP value of 0.69).  The metabolism of diprenorphine has been studied previously with 
different radiolabelled analogues of the molecule (Figure 4). Diprenorphine has been labelled 
with 11C at the C17 position of the molecule[16] (N-[11C]diprenorphine), however it has been 
suggested that diprenorphine is rapidly metabolised via N-dealkylation[17] resulting in the 
loss of the radiolabelled moiety.  More recently an automated synthesis of an 18F fluorinated 
analogue, 6-O-[2-[18F]fluoroethyl)-6-O-desmethyldiprenorphine ([18F]fluoroethyl-
diprenorphine), was described[18]. [18F]fluoroethyl-diprenorphine was shown to have 
similarities in the pharmacokinetics and receptor binding properties to [6-O-methyl-
11C]diprenorphine.  However [18F]fluoroethyl-diprenorphine showed lower brain uptake and  
rapid metabolism, with the radio-metabolites accounting for 20% of the radioactive signal in 
mouse brain 30 minutes after administration of the tracer[18]. The position of the 11C 
radiolabel at the C6 position means that it is less susceptible to metabolism (compared to N-
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Figure 4: Radiolabelled analogues of diprenorphine.  
Predicting radiotracer stability and metabolism in vivo can be challenging, however 
experiments using pooled human liver microsomes to ‘digest’ the radiotracer can be used to 
give an insight into what metabolites of the radiotracer might be expected in vivo. Bio-
transformations are evoked by exposing [11C]diprenorphine to pooled human liver 
microsomes, a source of the cytochrome P450 enzyme, and uridine glucuronosyl transferase 
(UGT) enzymes, both of which are important enzymes involved in the expulsion of foreign 
chemicals/drugs in the body. In addition computational programs can be used to predict the 
most likely chemical transformations that occur on a molecule during phase 1 or phase 2 
metabolism. These predictions are made using specialised computer software such as Meteor 
Nexus metabolite prediction software.  
A method to accurately and reproducibly measure [11C]diprenorphine metabolites 
using in line SPE and HPLC analysis has been developed. The metabolites of 
[11C]diprenorphine from clinical scans have been compared with in silico predictions, as well 
as simulated metabolism of [11C]diprenorphine using pooled human liver microsomes. The 
major radio-metabolite of [11C]diprenorphine has also been identified by matrix-assisted laser 
desorption/ionisation mass spectroscopy (MALDI-MS) as [11C]diprenorphine-3-glucuronide.    
Materials and Equipment 
Diprenorphine standards were purchased from Tocris Bioscience (Oxfordshire, U.K). 
Pooled human liver microsomes, Bovine serum albumin, UGT reaction solution A and UGT 
reaction solution B were all purchased from BD Biosciences (U.S). Sodium dihydrogen 
phosphate buffer, HPLC grade methanol and sodium hydroxide were purchased from Sigma 
Aldrich Company LTD (Dorset, U.K). Acrodisc CR 4 mm syringe filters with a 0.45 µm 
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HPLC analysis was performed on a Shimadzu Prominence HPLC system running 
Laura 3 software from LabLogic (South Yorkshire, UK) and LC solutions from Shimadzu 
LTD, UK. The HPLC system was run with a CBM-20A controller, a LC-20AB solvent 
delivery system, an SPD-20A absorbance detector and SIL-20A auto sampler. A dual BGO 
coincidence detection and a flow-count radio HPLC detection system were both purchased 
from Bioscan (Washington DC, US). An ACE 5 C18 HL 150 mm x 4.6 mm HPLC column 
(Product code: ACE-121-1546) was used and purchased from Hichrom (Berkshire, UK).   
A PK121R centrifuge was purchased from Thermo Fisher Scientific LTD 
(Massachusetts, US) and a 1470 Automatic Gamma Counter (AGC) was purchased from 
PerkinElmer (Massachusetts, US).  
Shim-Pack MAYI-C4 SPE cartridges (Product code: 099-01586-15) were purchased 
from Shimadzu LTD, UK, Isolute PH SPE packing material (Product code: 9360-0025) was 
purchased from Biotage (Uppsala, Sweden) and C18 SPE packing material (Product code: 
WAT020594) was purchased from Waters LTD (Hertfordshire, UK). Empty SPE column 
assemblies and fittings (30 mm L x 4.6 mm ID, Product code: AQ0-7262) were purchased 
from Phenomenex (Macclesfield, UK).  
Methods 
[6-O-methyl-11C]diprenorphine ([11C]diprenorphine) production  
[11C]Diprenorphine was synthesised according to a previously reported method[10] 
with some adaptations made to the radiochemistry and automated on a GE TRACERlab FXFE 
radiochemistry system[19]. The product was formulated for human administration and 
produced in line with good manufacturing practice (GMP) guidelines.  
[11C]Diprenorphine metabolite analysis for PET scans. 
[11C]Diprenorphine metabolites were analysed in discrete blood samples by in-line 
SPE followed by HPLC analysis. Discrete blood samples were spun down in a centrifuge at 
4000 g for 2 minutes at 20 ˚C. Following this, 2 mL of the plasma layer was extracted and 
added to 3 mL of sodium dihydrogen phosphate buffer (NaH2PO4, 5 mM) which was pre-
spiked with stable diprenorphine (15 µL of 1 mg/ml solution). The sample was then loaded 
onto a 5 mL stainless steel loop with the injection valve in the load position (Figure 1). Next 
the injection valve was switched to the inject position and the SPE mobile phase (NaH2PO4 ,5 
mM at a flow rate of 1 mL/min) swept the sample onto a pre-packed stainless steel SPE 
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column (3 x 0.48 cm) containing a C18 bulk packing material over a period of 5 minutes 
(Figure 2). It should be noted that SPE columns packed with Phenyl and with C4 stationary 
phases were also used for different experiments. The SPE column was then washed for a 
further 3.5 minutes with NaH2PO4 at 1 mL/min. The liquid from the SPE load and SPE 
washing steps containing plasma proteins and the most polar metabolites was collected in a 
pre-weighed vial containing sodium hydroxide (NaOH, 5M, 50 µL). 5 mL aliquots of the 
SPE breakthrough were then taken weighed and counted in a well counter. The SPE column 
was then eluted in the reverse direction onto an ACE-5 C18 HL HPLC column with 
methanol:NaH2PO4 (60:40) changing to 80:20 over the first 2.5 minutes. The HPLC eluent 
was monitored for UV absorbance at 254 nm and collected into fractions (1.6 mL and 2.4 
mL) which were counted in a 10 well automatic gamma counter (AGC) in which one position 
was left empty for background corrections.  
In order to assess the suitability of the SPE column being used, radioactive recovery 
measurements of the whole system (SPE and HPLC) were performed. This was done by 
injecting a sample of [11C]diprenorphine on to the whole system and measuring the 
radioactivity from the SPE breakthrough (measured in the well counter) and HPLC eluent 
from the column (collected into fractions and measured in the AGC). Radioactivity 
measurements from the AGC and the well counter were processed and recoveries were 
calculated by comparing the radioactivity of the [11C]diprenorphine injected onto the system 
to the decay corrected radioactivity in the SPE breakthrough aliquots and HPLC eluent from 
the column. 
The research study was approved by Stockport NHS Research Ethics Committee 
(reference 09/H1012/44) and permission granted by ARSAC (radiation protection agency).         
Production of [11C]diprenorphine metabolites by means of digest, using pooled 
human liver microsomes   
[11C]diprenorphine metabolites were generated by performing a digest using pooled 
human liver microsomes. To a centrifuge tube containing pooled human liver microsomes 
(25 µL, approximately 0.5 mg) UGT reaction mixture solution A (200 µL, containing 25 mM 
UDPGA) and UGT reaction mixture solution B (82 µL, containing 5X-UGT assay buffer 
with alamethicin) was added. [11C]diprenorphine  and stable diprenorphine (10 µL of 1 
mg/mL) were added to the assay followed by water (175 µL) and bovine serum albumin (175 
µL). The digestion was then incubated in a water bath (37 ˚C) for 45 minutes to 1 hour after 
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which the digestion was terminated with the addition of acetonitrile (500 µL). The reaction 
mixture was then spun at 16,060 g for 5 minutes at 4 ˚C after which the reaction mixture was 
separated from the microsome pellets. Next the reaction mixture was filtered through an 
Acrodisc CR 4 mm syringe filter with a 0.45 µM PTFE membrane then analysed via in-line 
SPE and HPLC. 
Results 
In Silico Analysis of [11C]diprenorphine metabolites  
A computational analysis of the metabolism of [11C]diprenorphine was performed 
using Meteor Nexus software (Lhasa LTD, Leeds, UK). Meteor Nexus is knowledge-based 
computational software used to predict molecular metabolism[20]. A chemical structure is 
submitted to the software which uses a knowledge base and takes information about the 
lipophilicity, functional groups and the likelihood of competing bio-transformations to 
predict the molecules metabolic fate. The software predicted that diprenorphine would 
undergo oxidative N-dealkylation   via the family of CYP450 enzymes as part of phase 1 
metabolism. The Nexus software also predicted oxidative O-dealkylation of diprenorphine, 
again by means of the enzyme family CYP450 and as part of phase 1 metabolism. Another 
predicted metabolite of diprenorphine was formed from the glucuronidation of the aromatic 
alcohol via a uridine 5'-diphospho-glucuronosyltransferase (UGT) enzyme as a result of 
phase 2 metabolism to diprenorphine-3-glucuronide. The metabolites predicted by Meteor are 
depicted in Figure 5.   
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 [11C]Diprenorphine metabolite analysis for PET 
Arterial blood samples were taken from patients at 5 minutes, 10 minutes, 20 minutes, 
30 minutes, 40 minutes and 60 minutes post [11C]diprenorphine injection. The blood samples 
were processed as detailed in the methods section and analysed by in-line C18 SPE and 
HPLC analysis. Figure 6 shows the profile of [11C]diprenorphine, the major metabolite 
[11C]diprenorphine-3-glucuronide and SPE breakthrough at various time points post injection. 
The data shows pooled averages for each time point for 55 [11C]diprenorphine PET scans.           
 
Figure 6: Metabolite profiles of [11C]diprenorphine, [11C]diprenorphine-3-glucuronide and SPE 
breakthrough (polar metabolites). Data is based on pooled averages of 55 [11C]diprenorphine PET scans.  
[11C]Diprenorphine recoveries with various SPE stationary phases 
Various SPE stationary phases were investigated to determine which would be 
optimal for trapping and eluting both parent and metabolite molecules with minimal loss. 
Three stationary phases were considered, a C4 phase (Shim-Pack MAYI-C4), a C18 phase 
and a phenyl stationary phase. The C18 and the phenyl stationary phases were packed into 
stainless steel column assemblies, whilst the MAYI C4 material was pre-packed. Recoveries 
on the whole system (SPE and HPLC) were performed as described in the methods section, 
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Phenyl (Isolute Ph) 76.2 ± 7.4 0.6 ± 0.3 8 
C4 (Shimadzu MAYI) 98.7 ± 2.9 3.9 ± 2.6 6 
C18 (Waters) 93.9 ± 4.5 1.4 ± 0.5 86 
Table 1: [11C]diprenorphine recoveries for different SPE column stationary phases. 
Discussion  
In silico analysis of [11C]diprenorphine metabolites  
The metabolites of diprenorphine which were predicted by Meteor Nexus metabolite 
prediction software can be seen, along with their cLogP values, in Figure 5. It is clear to see 
that the cLogP values for the metabolites are all lower than that of the parent diprenorphine 
molecule (cLogP = 2.57). We would therefore expect that the metabolites of diprenorphine 
would elute before the parent molecule on a C18 phase HPLC column and this is what we do 
observe (HPLC chromatograms available in supplementary data). Meteor Nexus predicts the 
loss of the cyclopropyl moiety from the molecule which has long been suspected as a major 
metabolite of diprenorphine[17]. The software also predicted a loss of a methyl group from 
the 6-methoxy position of diprenorphine. If this was to happen with [11C]diprenorphine we 
would lose the 11C radiolabel. Finally, glucuronidation of diprenorphine at the 3-hydroxy 
position to produce [11C]diprenorphine-3-glucuronide is predicted. We would anticipate that 
glucuronidation would occur at this position as it is the more acidic and reactive hydroxyl 
group.    
[11C]diprenorphine metabolites were generated  using a digestion method with hepatic 
microsomes and isolated as described in the methods section and the sample was analysed by 
MALDI-MS. The analyte (0.5 µL) was spotted onto a plate along with a matrix of α-cyano-4-
hydroxycinnamic acid (CHCA), in 1:1:0.05 (water:acetonitrile:trifluoroaceticacid). The 
results showed 3 peaks of note, the major peak in the analysis at m/z 426 represents 
[diprenorphine+H]+ and the peak at m/z 849 is the diprenorphine dimer. The peak at m/z 602 
is diprenorphine glucuronide, thought to be the major metabolite Figure 7. 
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Figure 7: MALDI MS spectrum of diprenorphine digest showing peaks for parent diprenorphine (m/z 
426), diprenorphine dimer (m/z 849) and diprenorphine glucuronide (m/z 602). 
We have also shown good agreement between the predicted in silico metabolism of 
diprenorphine and the in vitro metabolism of [11C]diprenorphine produced by hepatic 
microsome digestion. The Meteor software predicted the formation of diprenorphine-3-
glucuronide via phase 2 metabolism and the UGT enzyme. We confirmed this was the case 
by performing a digestion of [11C]diprenorphine with hepatic microsomes and confirmed the 
formation of  [11C]diprenorphine-3-glucuronide by MALDI-MS analysis. By identifying the 
major metabolite of [11C]diprenorphine we can start to answer important questions such as 
will [11C]diprenorphine-3-glucuronide cross the blood brain barrier, and if it does will it 
compete with [11C]diprenorphine for available opioid receptor sites? The cLogP of 
[11C]diprenorphine-3-glucuronide (cLogP = 0.69) suggests that its passage across the blood 
brain barrier is unlikely not taking into account transporter proteins. The pharmacology of 
[11C]diprenorphine-3-glucuronide is unclear, however we can compare how other 
glucuronides of opioids act on opioid receptors.  For example morphine-3-glucuronide has 
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been shown to have a low affinity at µ-receptors[21] whereas buprenorphine-3-glucuronide 
was reported to have some biological activity which could contribute to the total 
pharmacology of buprenorphine[22]. More work is required to analyse the blood brain barrier 
permeability and affinity diprenorphine-3-glucuronide may have on opioid receptors.               
[11C]Diprenorphine metabolite analysis for PET 
Figure 6 shows the profile of [11C]diprenorphine, the major metabolite 
[11C]diprenorphine-3-glucuronide and of the SPE breakthrough at various time points post 
[11C]diprenorphine intravenous injection in human volunteers. From Figure 6 we can see that 
the percentage of [11C]diprenorphine at 5 minutes post injection is around 70 % and 
[11C]diprenorphine-3-glucuronide accounts for 25 % of the radioactivity at this time- point. 
As we would expect, the percentage of [11C]diprenorphine falls at later time-points finally 
reaching 34 % at 60 minutes and the percentage of [11C]diprenorphine-3-glucuronide 
increases until a plateau of 52 % is reached at 30 minutes. The amount of [11C]diprenorphine-
3-glucuronide at 60 minutes post injection remains at 52 %. The SPE breakthrough accounts 
for 4 % of the activity at 5 minutes post injection which increases to 13 % at 60 minutes. This 
fraction contains the most polar metabolites which are not retained by the SPE and this polar 
radio metabolite could be [11C]MeOH, produced from O-dealkylation of [11C]diprenorphine 
as predicted by Meteor Nexus software. 
Our metabolite data from [11C]diprenorphine PET scans is in agreement with that 
reported by Sadzot et al and Jones et al[6, 14] in which we also see a decrease of the parent 
[11C]diprenorphine fraction over the 90 minute period of the scan corresponding with the 11C 
radiolabelled metabolites increasing over that same time period. Similarly we also observe a 
broad 11C radiolabelled metabolite peak eluting prior to [11C]diprenorphine in the HPLC 
analysis (Figure S1) which can be interpreted as a more polar substance and possibly two 11C 
radiolabelled metabolites.   
[11C]Diprenorphine recoveries with various SPE stationary phases   
Table 1 shows [11C]diprenorphine recovery measurements for the SPE stationary 
phases tested. We began by investigating the C4 (MAYI) pre-packed SPE column which is 
designed for biological sample pre-treatment. The MAYI SPE cartridges have a packing 
material in which the interior of the pore is modified with C4 groups and the outer silica 
surface is coated with a hydrophilic polymer. Plasma proteins should be unable to access the 
pore and do not adhere to the polymer coating making them easy to elute whilst low 
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molecular weight molecules (such as diprenorphine) will enter the pores and be retained. 
From Table 1 we can see that on average we saw good [11C]diprenorphine recoveries, 98.7 % 
(n = 6). However we found that a significant amount of the parent was breaking through (3.9 
% ± 2.6 %). The next SPE stationary phase was the phenyl reverse phase packed into 
stainless steel SPE column assemblies, a set-up which has been used previously for 
[11C]diprenorphine PET studies. A lower average percentage of [11C]diprenorphine recovery 
was observed with this phase (76.2 % ± 6.8%, n = 8). Interestingly this SPE  stationary phase 
has been used previously for a [11C]diprenorphine PET study where it was reported that > 98 
% of total plasma activity was retained by the SPE[6]. However when we used the phenyl 
stationary phase it was discovered that the recoveries were low for a similar in line SPE 
HPLC set-up. [11C]Diprenorphine was retained strongly by the phenyl phase likely owing to 
the π-π interactions between the analyte and the phenyl phase. However [11C]diprenorphine 
was not completely removed from the SPE column during the elution step as evidenced by 
the low recovery (76.2 % ± 7.4). The phenyl reverse phase also had a lower average 
percentage of SPE breakthrough with 0.6 % ± 0.3 % compared to the C4 and C18 phases. 
Finally we investigated a C18 stationary phase packed in-house. The C18 stationary phase 
showed good recoveries with an average of 93.9 % ± 4.5 % (n = 86) of the radioactivity 
recovered and only 1.4 % ± 0.5 % of radioactivity breaking through the SPE. If we compare 
the percentage of SPE breakthrough of [11C]diprenorphine in plasma for the C18 SPE column 
with the MAYI C4 SPE column we can see that much more of the radioactivity is retained by 
the C18 material. This may suggest that the parent ([11C]diprenorphine) could be breaking 
through the C4 cartridge possibly in a plasma protein bound form.   
Conclusion 
A method is described to measure the metabolites of the PET radiotracer 
[11C]diprenorphine via an in-line SPE method followed by HPLC analysis. After assessing 
various stationary phases of C4, phenyl and C18, we concluded that the C18 phase packed 
into a stainless column assembly (30 mm L x 4.6 mm ID) was the most optimal of the 
conditions investigated. This conclusion was made by investigating the loading, retention and 
subsequent elution of [11C]diprenorphine from the SPE as well as performing experiments to 
measure the recovery of [11C]diprenorphine. 
We believe that our method of [11C]diprenorphine metabolite analysis should be the 
method of choice for [11C]diprenorphine PET scanning, offering a reliable and robust 
approach. 11C radiometabolites can be successfully quantified with minimal loss to the 
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system, using SPE to clean-up and concentrate the sample before analysis by analytical 
HPLC.    
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